Treating octogenarian and nonagenarian acute myeloid leukemia patients - Predictive prognostic models

Cancer

Volumn 115, Issue 11, 2009, Pages 2472-2481

  Harb, Antoine J ^a   Tan, Wei ^a   Wilding, Gregory E ^a   Ford, LaurieAnn ^a   Sait, Sheila N J ^a   Block, AnneMarie W ^a   Barcos, Maurice ^a   Wallace, Paul K ^a   Wang, Eunice S ^a,b   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute myeloid leukemia; Nonagenarian; Octogenarian; Prognostic models

Indexed keywords

ALBUMIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; OBLIMERSEN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; AGING; ALBUMIN BLOOD LEVEL; ARTICLE; BLAST CELL; CANCER PALLIATIVE THERAPY; CELL STRUCTURE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTINUOUS INFUSION; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC CELL TRANSPLANT COMORBIDITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

AGE FACTORS; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MODELS, STATISTICAL; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 66649108827     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24285     Document Type: Article

References (37)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908-1915. (Pubitemid 46854425)
2. Roboz GJ. Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther. 2007;7:285-295. (Pubitemid 46499211)
3. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91:1513-1522. (Pubitemid 44736118)
4. Melchert M. Managing acute myeloid leukemia in the elderly. Oncology (Williston Park). 2006;20:1674-1682; discussion 1683-1684, 1687.
5. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996;93:89-95. (Pubitemid 26132390)
6. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001;115:25-33. (Pubitemid 32995089)
7. Mori M, Ohta M, Miyata A, et al. Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma. 2006;47:2062-2069. (Pubitemid 44650081)
8. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098. (Pubitemid 43297348)
9. Feinstein AR. Symptomatic patterns, biologic behavior, and prognosis in cancer of the lung. Practical application of Boolean algebra and clinical taxonomy. Ann InternMed. 1964;61:27-43.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
11. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score [serial online]. BMC Cancer. 2004;4:94. (Pubitemid 40180260)
12. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109:1376-1383. (Pubitemid 46466565)
13. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919. (Pubitemid 41510773)
14. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136:624-627. (Pubitemid 46148199)
15. Malfuson JV, Etienne A, Turlure P, et al; Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806-1813.
16. Atlanta, Ga: Centersfor Disease Control and Prevention; 2008. Available at http://www.cdc.gov
17. Srivastava R. The art of letting go. N Engl J Med. 2007;357:3-5. (Pubitemid 47026728)
18. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336. (Pubitemid 35429670)
19. Larson RA, Dodge RK, Burns CP, et al. A 5-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995;85:2025-2037.
20. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
21. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454-462. (Pubitemid 12048693)
22. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809-816. (Pubitemid 38500200)
23. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760-761.
24. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268-1274. (Pubitemid 19220128)
25. Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. Hematol Oncol. 1992;10:251-260. (Pubitemid 23050932)
26. Hernandez-Boluda JC, Sierra J, Esteve J, Nomdedeu B, Montserrat E. Treatment of elderly patients with AML: results of an individualized approach. Haematologica. 1998;83:34-39. (Pubitemid 28096500)
27. Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. J Exp Clin Cancer Res. 2004;23:447-454.
28. Orlandi E, Lazzarino M, Morra E, et al. Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients. Acta Haematol. 1990;84:144-148. (Pubitemid 20361940)
29. Tucker J, Thomas AE, Gregory WM, et al. Acute myeloid leukemia in elderly adults. Hematol Oncol. 1990;8:13-21. (Pubitemid 20087126)
30. Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. Neoplasma. 2005;52:411-414.
31. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129-5135. (Pubitemid 46900774)
32. Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007;110:1729-1737. (Pubitemid 47557297)
33. Siddiqui A, Heinzerling J, Livingston EH, Huerta S. Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg. 2007;194:362-366. (Pubitemid 47212033)
34. Lee KH, Lee JS, Suh CW, et al. Prognostic factors of acute myelocytic leukemia: an analysis of 132 patients in a single institution. J Korean Med Sci. 1996;11:222-232. (Pubitemid 126700861)
35. Peterson L, Dehner LP, Brunning RD. Extramedullary masses as presenting features of acute monoblastic leukemia. Am J Clin Pathol. 1981;75:140-148. (Pubitemid 11142651)
36. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.
37. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and highrisk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124. (Pubitemid 46435390)